ERBB2 and neoplasm: However, more than 50% of patients with IBC develop lymphedema following this treatment regime.2 While surgical axillary clearance is the current standard, recent research shows that outcomes of IBC are mainly driven by tumor subtype3 and pathological complete response (pCR), facilitated by chemotherapeutic advances and anti-HER2 targeted therapies.4 Hence, deescalating ALND in selected patients with IBC with nodal complete pathological response (ypN0) may be a possibility.